Skip to main content
SpringerLink
Log in

Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias

  • Original Articles
  • Myeloid Leukemia, CD33, Immunotoxin, Gelonin, M195, HuM195
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

M195 antibodies recognize CD33, an antigen present on acute myeloid leukemia blasts as well as some myeloid progenitor cells, but not on the ultimate hematopoietic progenitor stem cell. Immunotoxins (IT) reactive with human myeloid leukemias were constructed by conjugating gelonin, a single-chain ribosome-inactivating protein, to murine and genetically engineered, humanized M195 antibodies via anN-succinimidyl-3-(2-pyridyldithio)-propionate linkage. No losses of gelonin cytotoxic activity or M195 binding activity were observed after conjugation of up to two toxin molecules per antibody. Toxin conjugates displayed specific, potent toxicity for CD33+ cells. The murine and humanized IT were not toxic to CD33− cells and were 600 and 4500 times more potent, respectively, than free gelonin in inhibiting CD33+ HL60 cells. Treatment of HL60 cells with 1 μg/ml HuM195-gelonin resulted in more than 1000 times lower colony formation; normal bone marrow mononuclear cell colonyforming units treated with HuM195-IT were reduced by a factor of 10. HL60 leukemia cells could be effectively purged from an excess of normal bone marrow cells. Exposure of target cells to IT for as little as 30 min was as effective as continuous exposure of IT for up to 6 days. However, measures of the efficacy of the immunotoxin were directly related to the length of time of observation after IT exposure and were inversely related to cell concentration. M195-gelonin immunoconjugates are potential candidates for therapeutic use in in vivo or ex vivo bone marrow purging of myeloid leukemias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Andrews RG, Torok-Storb B, Bernstein ID (1983) Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62: 124

    PubMed  Google Scholar 

  2. Barbieri L, Stirpe F (1982) Ribosome-inactivating proteins from plants: properties and possible uses. Cancer Surv 1: 490

    Google Scholar 

  3. Bernstein ID, Singer JW, Andrews RG, Keeting A, Powell JS, Bjornson BH, Cuttner J, Najfeld V, Reaman G, Raskind W, Sutton DMC, Fialkow PJ (1987) Treatment of acute myeloid leukemia cells in vitro with monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 79: 1153

    PubMed  Google Scholar 

  4. Blakey DC, Thorpe PE (1988) An overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunoconjugates Radiopharm 1: 1

    Google Scholar 

  5. Blattler WA, Lambert JM, Goldmacher VD (1989) Realizing the full potential of immunotoxins. Cancer Cells 1: 50

    PubMed  Google Scholar 

  6. Brigotti M, Rambelli F, Zamboni M, Montanaro L, Sperti S (1989) Effects of alpha-sarcin and ribosome inactivating proteins on the interaction of elongation factors with ribosomes. Biochem J 257: 723

    PubMed  Google Scholar 

  7. Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, Clark RE, Waldmann TA (1991) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88: 2663

    PubMed  Google Scholar 

  8. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52: 6761

    PubMed  Google Scholar 

  9. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA (1993) A phase 1 B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 83 (in press)

  10. Chapman PB, Scheinberg DA, DiMaggio JJ, Houghton AN (1991) Unconjugated monoclonal antibodies as anticancer agents. In: Oettgen HF (ed) Immunology and allergy clinics of north america. Saunders, Philadelphia, p 257

    Google Scholar 

  11. Co MS, Deschamps M, Whitley RJ, Queen C (1991) Humanized antibodies for antiviral therapy. Proc Natl Acad Sci USA 88: 2869

    PubMed  Google Scholar 

  12. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C (1992) Chimeric and humanized antibodies with specificity for the CD33 antigen. J Hematol 148: 1149

    Google Scholar 

  13. Co MS, Scheinberg DA, Avdalovic NM, McGraw KJ, Vasquez MH, Caron PC, Queen C (1993) Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol 30: 1361

    PubMed  Google Scholar 

  14. Divgi CR, Minniti JG, Old LJ, et al. (1989) Internalization of radiolabeled monoclonal antibody (mAb) into specific cells: effect of the radionuclide and antibody form. Cancer Res [Suppl] 30: 494a

    Google Scholar 

  15. Engert A, Brown A, Thorpe P (1991) Resistance of myeloid leukemia cell lines to ricin A-chain immunotoxins. Leukemia Res 15: 1079

    Google Scholar 

  16. Gabrilove JL, Wong G, Bollenbacher E, White K, Kojima S, Wilson EL (1993) Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-beta 1 on human progenitor cells. Blood 81: 909

    PubMed  Google Scholar 

  17. Goldmacher VS, Lambert JM, Blattler WA (1992) Evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. Biochem Biophys Res Commun 183: 758

    PubMed  Google Scholar 

  18. Griffin D, Linch D, Sabbath K, Larcom P, Schlossman SF (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8: 521

    PubMed  Google Scholar 

  19. Grossbard ML, Lambert JM, Goldmacher VS, Blattler WA, Nadler LM (1992) Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti B4-blocked ricin. Cancer Res 52: 4200

    PubMed  Google Scholar 

  20. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863

    PubMed  Google Scholar 

  21. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA, Taylor JA, Nadler LM (1992) Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79: 576

    PubMed  Google Scholar 

  22. Hertler AA, Frankel AE (1989) Immunotoxins: a clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1932

    PubMed  Google Scholar 

  23. La Russa VF, Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG (1992) Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long term marrow culture. Exp Hematol 20: 442

    PubMed  Google Scholar 

  24. Peiper SC, Ashmun RA, Look AT (1988) Molecular cloning expression and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 72: 314

    PubMed  Google Scholar 

  25. Preijers FWMB, De Witte T, Wessels JMC, Gast GC de, Van Leeuwen E, Capel PJA, Haanen C (1989) Autologous transplantation of bome marrow purged in vitro with anti-CD7-(WT1)ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 74: 1152

    PubMed  Google Scholar 

  26. Raso V, Watkins SC, Slayter H, Fehrmann C (1987) Intracellular pathways of ricin A chain cytotoxins. Ann N Y Acad Sci 507: 172

    PubMed  Google Scholar 

  27. Reichman L, Clark M, Waldman H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332: 323

    PubMed  Google Scholar 

  28. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, Ritz J (1992) Human bone marrow depleted of CD33-positive cells mediated delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 79: 2229

    PubMed  Google Scholar 

  29. Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, Bartholomew R (1991) A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3: 6

    PubMed  Google Scholar 

  30. Rosenblum MG, Kohr W, Beatty K, Beatty WF, Friedman P (1993) Sequencing, cloning and expression of recombinant gelonin toxin. Proc Am Assoc Cancer Res 34: 478

    Google Scholar 

  31. Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J (1991) Anti-MY9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 77: 2404

    PubMed  Google Scholar 

  32. Scheinberg DA, Tanimoto M, Mc Kenzie S, Strife A, Old LJ, Clarkson BD (1989) Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 3: 440

    PubMed  Google Scholar 

  33. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9: 478

    PubMed  Google Scholar 

  34. Schwartz MA, Scheinberg DA, Houghton AN (1992) Monoclonal antibody therapy. In: Longo D (ed) Cancer chemotherapy and biological response modifiers, vol 13. Elsevier Amsterdam p 156

    Google Scholar 

  35. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA (1993) Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11: 294

    PubMed  Google Scholar 

  36. Sivam G, Pearson JW, Bohn W, Oldham RK, Sadoff JC, Morgan AC (1987) Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res 47: 3169

    PubMed  Google Scholar 

  37. Stirpe F, Olsnes SE, Pihl A (1980) Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. J Biol Chem 255: 6947

    PubMed  Google Scholar 

  38. Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ (1989) Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 3: 339

    PubMed  Google Scholar 

  39. Trowbridge IS, Domingo DL (1982) Prospects for the clinical use of cytotoxic monoclonal antibody. Conjugates in the treatment of cancer. Cancer Surv 1: 544

    Google Scholar 

  40. Uckun FM, Gail-Peczalska KJ, Kersey JH, Houston LL, Vallera DA (1986) Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J Exp Med 163: 347

    PubMed  Google Scholar 

  41. Vitetta E (1990) Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS. J Clin Immunol [Suppl] 10: 15S

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, 10021, New York, NY, USA

    Kimberly J. McGraw & David A. Scheinberg

  2. Immunopharmacology Section, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 41, Department of Clinical Immunology and Biological Therapy, 77030, Houston, TX, USA

    Michael G. Rosenblum & Lawrence Cheung

Authors
  1. Kimberly J. McGraw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael G. Rosenblum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David A. Scheinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

These studies were supported in part by the Lucille P. Markey Charitable Trust, ACS Grant No. IM551, NIH PO1CA33049, NIH RO1CA55349. Research conducted, in part, by the Clayton Foundation for Research. David A Scheinberg is a Lucille P. Markey Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McGraw, K.J., Rosenblum, M.G., Cheung, L. et al. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother 39, 367–374 (1994). https://doi.org/10.1007/BF01534423

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01534423

Key words

Search

Navigation